Candel Therapeutics (CADL) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Candel Therapeutics is set to announce its Q2 2025 earnings on August 12th, with analysts expecting a loss of ($0.17) per share for the quarter.
• After reporting better-than-expected earnings of $0.13 per share in May, Candel's stock has decreased by 1.2%, trading at $6.24.
• The company has received a series of upgrades from analysts, currently holding an average rating of "Buy" with a target price of $22.00.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37. On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Trading Down 1.8%

NASDAQ:CADL traded down $0.11 during midday trading on Thursday, reaching $5.85. 105,472 shares of the stock traded hands, compared to its average volume of 1,063,734. The company has a fifty day moving average of $5.77 and a 200 day moving average of $6.39. Candel Therapeutics has a 12 month low of $3.79 and a 12 month high of $14.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.64 and a current ratio of 4.64. The stock has a market capitalization of $293.24 million, a P/E ratio of -4.37 and a beta of -0.88.

Wall Street Analysts Forecast Growth

CADL has been the subject of a number of recent analyst reports. Brookline Capital Management upgraded shares of Candel Therapeutics to a "strong-buy" rating in a report on Wednesday, July 9th. Wall Street Zen upgraded shares of Candel Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright upgraded shares of Candel Therapeutics to a "buy" rating and set a $23.00 price objective for the company in a report on Monday, June 30th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $22.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Candel Therapeutics by 37.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company's stock worth $95,000 after buying an additional 4,583 shares during the period. Rhumbline Advisers grew its position in shares of Candel Therapeutics by 26.8% in the 1st quarter. Rhumbline Advisers now owns 33,302 shares of the company's stock worth $188,000 after buying an additional 7,030 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of Candel Therapeutics in the 1st quarter worth about $59,000. 13.93% of the stock is currently owned by institutional investors.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.